Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568719 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
A Phase 3 study of Hemophilia A and Hemophilia B, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 16
- Study locations
NCT05568719: Recruiting Phase 3 study of Hemophilia A and Hemophilia B, sponsored by Pfizer.
NCT05568719 is a Phase 3 study of Hemophilia A and Hemophilia B that is actively recruiting participants, run by Pfizer. The registered enrollment target is 173 participants, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (99% higher). The trial reports 16 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05568719, a Phase 3 study of Hemophilia A and Hemophilia B, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 16
- Study locations
Study Summary
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Testing of hepatic AAV Vector integration
Study Locations (16)
California
- The Regents of the University of California||UC Davis Health - Rancho Cordova
- UC Davis Health - Sacramento
- UC Davis Ambulatory Care Clinic - Sacramento
- UC Davis Hemophilia Treatment Center - Sacramento
- UC Davis Medical Center - Sacramento
- UCSF Outpatient Hematology Clinic - San Francisco
Florida
- USF Health Morsani Center For Advanced Healthcare - Tampa
- The University of South Florida Board of Trustees - Tampa
New York
- Cornell University||Joan & Sanford I. Weill Medical College - New York
- Weill Cornell Medical College-New York Presbyterian Hospital - New York
New South Wales
- Royal Prince Alfred Hospital - Camperdown
- Sydney Local Health District (RPAH Zone) - Camperdown
Mississippi
- Mississippi Center For Advanced Medicine - Madison
Pennsylvania
- The Childrens Hospital of Philadelphia Division of Hematology - Philadelphia
Washington
- Washington Institute for Coagulation - Seattle
İ̇zmir
- Ege Universitesi Hastanesi - Izmir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2040-02-25 |
| Phase | Phase 3 |
What NCT05568719 shows while recruiting
NCT05568719 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (99% higher).
The record links to 2 conditions, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Testing of hepatic AAV Vector integration is the first listed.
NCT05568719 lists 16 locations in 8 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT05568719 about?
NCT05568719 is a clinical study titled "Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively". A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participan...
What is the current status of trial NCT05568719?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2022-12-28. Estimated completion is 2040-02-25.
What conditions does trial NCT05568719 study?
This clinical trial studies the following conditions: Hemophilia A, Hemophilia B.
What interventions are being tested in trial NCT05568719?
The interventions under investigation include: Testing of hepatic AAV Vector integration (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05568719?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05568719 being conducted?
This trial has 16 study locations across California, Florida, Mississippi, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05568719's enrollment target sits among peer trials
173 9th of 42 higher than 34 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI